Xencor Cuts IPO Price, Still Raises $70M for Antibody Programs
Shrugging off pre-Thanksgiving initial public offering (IPO) jitters, which saw four biotechs yank their planned IPOs last month, Xencor Inc. exited Tuesday with a $70 million offering to support clinical development of FC-engineered antibody candidates XmAb5871 and XmAb7195.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter